Skip to main content
. 2021 Jun 2;143(22):2188–2204. doi: 10.1161/CIRCULATIONAHA.121.053350

Figure 2.

Figure 2.

The SGLT2 inhibitors are potent inhibitors of the late component of the cardiac sodium channel current (late-INa). A and B, Representative whole-cell patch-clamp recordings of H2O2-induced late-INa and the inhibitory effects of 5 µmol/L tetrodotoxin (TTX, A) and 1 or 10 µmol/L empagliflozin (empa, B). C, Concentration-inhibition curves for empa on peak- and late-INa. D, Grouped data showing the frequency-dependent relationship of peak- vs late-INa inhibition by 1 µmol/L empa. E and F, Representative whole-cell patch-clamp recordings of H2O2-induced late-INa and the inhibitory effects of 1 or 10 µmol/L dapagliflozin (dapa, E) and canagliflozin (cana, F). G, Concentration–late-INa inhibition curves for empagliflozin, dapagliflozin, and canagliflozin. For all experiments, n=5 to 7 cells per group, *P<0.05 compared with the vehicle control, paired t test. Insets in B, E, and F are expanded sections illustrating the lack of effect of these drugs on peak-INa. AUC indicates area under the curve; IC50, half-maximal inhibitory concentration; and peak INa, maximum peak sodium current amplitude.